Boston Scientific aims to acquire Lumenis ’global laser surgery industry, through a $ 1.07 billion contract that will include its systems for ear, nose and throat procedures and Moses’ laser treatment for kidney stone fractures.
The medtech company has been a trading partner with Lumenis for more than 20 years, and has previously distributed Lumenis products in the US and Japan. Now, Boston Scientific plans to combine these laser systems with other urologic devices in its lineup.
“Moses’ laser technology, combined with our LithoVue single-use digital flexible ureteroscope and the complete kidney stone management package, will deliver our strategy for our stone consent, ”said Meghan Scanlon, president of urology and pelvic health at at Boston Scientific.
“With the growth of complex double-digit annuals from 2015 to 2019, we look forward to adding an innovative Lumenis laser package, a talented workforce and a center of surgical laser excellence to our organization. , ”Said Scanlon.
LOVE: Boston Scientific is getting back $ 800M by selling BTG’s antidote business
The acquisition will also expand Boston Scientific’s footprint in Europe and Asia, she said, while the entire Lumenis surgery industry is expected to generate around $ 200 million in net sales this year. The corporate owners of Israel-based company Baring Private Equity Asia will own the Lumenis global beauty and ophthalmology departments.
Lumenis ’Moses system targets large kidney stones through a minimally invasive lithotripsy procedure, by locating the stone with a span and using a laser to dislodge it. The companies estimate that more than 1 in 10 adults develop kidney stones each year.
Following the completion of the advance cash contract, which was expected in the second half of this year, Boston Scientific plans to sell Lumenis laser and fiber optics systems worldwide.
Earlier in the week, Boston Scientific closed its deal for Preventice, a maker of affordable heart monitors, through a paper transaction that raised $ 925 million in additional cash. on up to $ 300 million in commercial milestone payments but even out to about $ 720 million in advance and $ 230 in milestones when accounting for a 22% equity allowance the company had before.